HeartCore Enterprises regains Nasdaq compliance with $3.6mln stockholders' equity.

HeartCore Enterprises, a Tokyo-based enterprise software and consulting services company, has received notice from Nasdaq that it has regained compliance with the $2,5 million minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. This follows the company's Quarterly Report on Form 10-Q, which reported stockholders' equity of $3,559,017. The matter is now closed.

HeartCore Enterprises, a Tokyo-based enterprise software and consulting services company, has recently received a notification from Nasdaq that it has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. This news follows the company's Quarterly Report on Form 10-Q, which reported stockholders' equity of $3,559,017. The matter is now closed.

The notification from Nasdaq confirms that HeartCore Enterprises satisfies the equity standard under Nasdaq Listing Rule 5550(b)(1), which requires certain companies to maintain stockholders' equity of at least $2.5 million. This compliance allows the company to continue its listing on the Nasdaq Capital Market without any immediate concerns regarding delisting.

HeartCore Enterprises has been actively working to meet the regulatory requirements set by Nasdaq. The company's recent quarterly report demonstrates its financial health and commitment to maintaining compliance with listing standards. This achievement is a significant milestone for the company, as it ensures its continued presence on the Nasdaq exchange.

Nasdaq's decision to allow HeartCore Enterprises to maintain its listing status is a testament to the company's financial stability and regulatory adherence. The company's ability to meet the equity requirement underscores its commitment to transparency and compliance, which are crucial for maintaining investor confidence.

HeartCore Enterprises has built a strong reputation in the enterprise software and consulting services sector. Its ability to meet regulatory requirements and maintain financial stability positions it well for future growth and expansion. As the company continues to develop its products and services, it will be essential for investors to monitor its ongoing compliance with Nasdaq's listing rules.

Reference List:
[1] https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-regains-compliance-applicable-nasdaq-listing
[2] https://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-sells-106506-shares-of-nasdaq-inc-ndaq-2025-08-21/